Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for patients and caregivers Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive primary analysis results from its registrational trial, KYSA-8, of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome (SPS). The data...

CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) plans to release its financial results and operating highlights for the three months ended March 31, 2026, on Thursday, May 7, 2026 prior to market open. Results will be communicated by news release and will be available on the Company’s website at www.enerflex.com and under the electronic profile of the Company on SEDAR+ and EDGAR at www.sedarplus.ca and www.sec.gov/edgar, respectively. Investors, analysts, members of the media, and other interested parties, are invited to participate in a conference call and audio webcast on Thursday, May 7, 2026 at 8:00 a.m. (MT), where members of senior management will discuss the Company’s results. A question-and-answer period will follow. To participate, register...

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) — Emerita Resources Corp. (“Emerita” or the “Company”) (TSXV: EMO) (OTCQX: EMOTF) (FSE: LLJA) has become aware of a press release dated April 21, 2026 issued by Denarius Metals Corp. (“Denarius”) pursuant to which Denarius has indicated its intention to make an increased offer to acquire all of the issued and outstanding common shares of Emerita (the “Shares”). Please see the Company’s press release dated April 13, 2026 for further details regarding the initial offer received from Denarius (the “Initial Offer”). Emerita has not received an additional written offer from Denarius following the receipt of the Initial Offer. The Board of Directors of Emerita (the “Board”), in consultation with its advisors, will determine the course of action that is in the best interests of Emerita and its shareholders....

PORTLAND, Tenn., April 21, 2026 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global leader in electrical infrastructure solutions for the energy transition market, announced today its participation in the following upcoming investor events: May 7, 2026: JP Morgan Virtual Fireside Chat Shoals’ CEO, Brandon Moss, and CFO, Dominic Bardos, will participate in a fireside chat with covering analyst Mark Strouse. Interested investors should contact their JP Morgan sales representative. May 13, 2026: Johnson Rice Virtual Fireside Chat Shoals’ VP of Finance & Investor Relations, Matt Tractenberg, and SVP of Sales, Karen Bazela, will participate in a fireside chat with covering analyst Marty Malloy. Interested investors should contact their Johnson Rice sales representative. May 27,...

Total Revenue growth of 13% year-on-year Adjusted EBITDAR Margin of 25% Operating Margin of 11% Liquidity to LTM Revenue ratio at 23%MEXICO CITY, April 21, 2026 (GLOBE NEWSWIRE) — Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO, “Aeroméxico” or the “Company”) today reported unaudited consolidated financial results for the three months ended March 31, 2026 (“1Q26”). These results are based on information available to us as of the date of this earnings release and are not a comprehensive statement of our financial results for the period presented. The Company has used the U.S. dollar, its functional currency, as the presentation currency for its consolidated financial statements. All figures are expressed in millions of U.S. dollars unless otherwise indicated. Andrés Conesa, Chief Executive Officer stated: “Aeroméxico...

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two Phase 1/2 trials of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Data from the daraxonrasib combination cohort will be presented in a late-breaking mini-symposium, and data from the monotherapy cohort will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting on April 21, 2026. Findings from both trials support daraxonrasib’s continued evaluation in the first line setting, demonstrating manageable safety and tolerability profiles...

TULSA, Okla., April 21, 2026 (GLOBE NEWSWIRE) — Matrix Service Company (Nasdaq: MTRX), a leading provider of engineering and construction services to the energy and industrial markets, announced today that it will release third quarter Fiscal 2026 results after market on Wednesday, May 6, 2026. On Thursday, May 7, 2026, at 10:30 a.m. Eastern time/9:30 a.m. Central time, Matrix Service Company will host a conference call to present and discuss the Company’s financial results and forward outlook. Earnings Conference Call instructions Investors and other interested parties can access a live audio-visual webcast using this webcasts link, or through the Company’s website at www.matrixservicecompany.com on the Investors Relations page under Events & Presentations. Please allow extra time prior to the call to visit the site and download...

WILMINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN) today announced the pricing of its initial public offering in the United States of 3,673,638 common shares at a public offering price of $4.50 per share and to certain investors, in lieu of common shares, pre-funded warrants to purchase 770,807 common shares at a purchase price of $4.4999 per pre-funded warrant, which represents the public offering price per share, minus the $0.0001 per share exercise price of each such pre-funded warrant. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Liberty, are expected to be approximately $20 million. In connection with the offering, Liberty has granted the underwriters a 30-day...